ストックスクリーナーアプリを入手
11.11
5.83%
-0.3801
Climb Bio Inc (CLYM) 最新ニュース
Climb Bio teases key Budoprutug, CLYM116 readouts at BioConnect - MSN
Why is Climb Bio stock gaining Friday? - MSN
Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $17 - Moomoo
Climb Bio launches $100M at-the-market common stock offering - scanx.trade
Climb Bio Establishes New At-the-Market Equity Program - TipRanks
Climb BioEnters Open Market Sale Agreement With JefferiesSEC Filing - TradingView
Climb Bio Launches $100 Million ATM Equity Program With Jefferies - TradingView
CLYM Reiterates by Wedbush -- Price Target Maintained at $17.00 - GuruFocus
Why Is Climb Bio Stock Gaining Friday? - Benzinga
BTIG raises Climb Bio stock price target to $20 on ITP trial data - Investing.com UK
Climb Bio, Inc. reports initial Phase 1b data show robust B cell depletion in ITP trial - Traders Union
Climb Bio reports positive initial Phase 1b data for budoprutug in ITP - grafa.com
Climb Bio (CLYM) Shows Promising Results in Phase 1b Trial for B - GuruFocus
Climb Bio reports initial trial data for ITP treatment budoprutug - Investing.com UK
Climb Bio Reports Encouraging Phase 1b Results for Budoprutug in ITP - Moomoo
Climb Bio Reports Encouraging Early Budoprutug ITP Data - TipRanks
Climb Bio reports encouraging Phase 1b ITP data; 250 mg cohort shows durable platelet gains - TradingView
Climb Bio reports initial trial data for ITP treatment budoprutug By Investing.com - Investing.com Canada
Climb Bio (CLYM) details early budoprutug Phase 1b/2a ITP results and risks - Stock Titan
Climb Bio Announces Initial Phase 1b Data Demonstrating - GlobeNewswire
CLYM Stock Price, Quote & Chart - ChartMill
[EFFECT] Climb Bio, Inc. SEC Filing - Stock Titan
Climb Bio (CLYM) files resale prospectus for 11.59M shares, including 2.106M warrant shares - Stock Titan
CLYM Initiates Coverage On by Guggenheim -- Rating Set at Buy - GuruFocus
Climb Bio (CLYM) reports 40,000-share option grant tied to RA Capital - Stock Titan
Climb Bio (CLYM) director Judith Dunn receives 40,000 stock options grant - Stock Titan
Director at Climb Bio (NASDAQ: CLYM) granted 40,000 options - Stock Titan
Climb Bio (CLYM) director receives stock options on 40,000 common shares - Stock Titan
Climb Bio (CLYM) awards director Douglas Williams 40,000 stock options - Stock Titan
Climb Bio (CLYM) director Alexander Cumbo awarded options on 40,000 shares - Stock Titan
Climb Bio (CLYM) director awarded 40,000 stock options grant - Stock Titan
Climb Bio Shareholders Approve Equity Plan Amendment, Reelect Directors - TipRanks
Climb Bio shareholders elect directors and approve equity plan amendment By Investing.com - Investing.com Nigeria
Climb Bio shareholders elect directors and approve equity plan amendment - Investing.com
Climb Bio (NASDAQ: CLYM) expands equity plan evergreen to cover pre-funded warrants - Stock Titan
CLYM Reiterated by BTIG -- Price Target Maintained at $19.00 - GuruFocus
Guggenheim initiates Climb Bio stock coverage with buy rating By Investing.com - Investing.com South Africa
BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Guggenheim initiates Climb Bio stock coverage with buy rating - Investing.com
Guggenheim Initiates Climb Bio at Buy With $35 Price Target - Moomoo
CLYM News | CLIMB BIO INC (NASDAQ:CLYM) - ChartMill
Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM) - The Globe and Mail
Climb Bio reports initial safety data for CLYM116 in IgAN trial By Investing.com - Investing.com South Africa
Climb Bio, Inc. Files Form 8-K with SEC – Corporate Information, Stock Details, and Emerging Growth Status - Minichart
Climb Bio stock dips despite initial CLYM116 safety data - Investing.com India
Climb Bio stock dips despite initial CLYM116 safety data By Investing.com - Investing.com Nigeria
Climb Bio Reports Positive Early-Stage Data for CLYM116 - TipRanks
Climb Bio reports initial safety data for CLYM116 in IgAN trial - Investing.com Australia
Climb Bio (NASDAQ: CLYM) advances CLYM116 toward Phase 2 IgAN trial - Stock Titan
Climb Bio, Inc. to Present CLYM116 Clinical Data and Development Plans at R&D Spotlight, Dosing in IgAN Patients Set to Begin Q3 2026 - Quiver Quantitative
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development - The Manila Times
6.83%
0.89%
大文字化:
|
ボリューム (24 時間):